Document is current
Any future updates will be listed below
-
Authors
Xu, Qian
Li, Mengyao
Li, Dong
Dai, Xiaoyu
Zhang, Yifei
Qu, Yi
-
Funding
Funding for this research was provided by:
Shandong Provincial Natural Science Foundation (#ZR2025QC1712)
Jinan Health High-Caliber Talent Project
- License Information
-
More Information
Article History
Received: 25 September 2025
Accepted: 21 April 2026
First Online: 2 May 2026
Declarations
:
: Cell Line Ethics: The original source (Zhong Qiao Xin Zhou Biotechnology) has confirmed that there was initial ethical approval for collection of human cells, and that the donors had signed informed consent. Human Ethics: The human cells (UC-MSCs) used in this study were approved by the Ethics Committee of Qilu Hospital, Shandong University. Title: Exploration and Comparison of UC-MSCs in Treating Dry Age-Related Macular Degeneration. Approval number: KYLL-202008-111. Date of approval: Aug 31, 2020. All participants provided informed consent, and this study adheres to the principles of the Declaration of Helsinki. Animal Ethics: The animal experimental procedures were approved by the Laboratory Animal Ethical and Welfare Committee of Qilu Hospital, Shandong University, and this study was reported in compliance with the ARRIVE guidelines 2.0. Title: Exploration and Comparison of UC-MSCs in Treating Dry Age-Related Macular Degeneration by Improving Retinal Pigment Epithelial Cell Dysfunction. Approval number: DWLL-2022-17. Date of approval: Sep 20, 2022.
: The authors declare no competing interests.
